Amgen reports a Phase 3 win with Sjögren’s drug candidate
Phase 3positiveDazodalibepPositive
AI Analysis
Summary
Amgen reported positive Phase 3 results for Dazodalibep, an acquired Horizon Therapeutics drug candidate, which succeeded in the first of two late-stage trials for Sjögren's syndrome.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
Succeeded in the first of two late-stage trials
Importance:8/10
Sentiment:
0.80
Phase 3 resultsautoimmune disorderSjögren's syndromeacquisition
Read the original article
Published by BioPharma Dive on September 22, 2026 6:31 PM